[{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline and MMV Present Positive Data on Treatment for Plasmodium Vivax Malaria in Children from 6 Months up to 15 Years of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Safety Monitoring Board Recommends Completion of Phase II Study to Evaluate the Efficacy and Safety of ARAKODA\u00ae (tafenoquine) for Treatment of Mild-Moderate Covid-19 Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"WallachBeth Capital LLC","pharmaFlowCategory":"D","amount":"$2.4 million","upfrontCash":"Undisclosed","newsHeadline":"60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Yale University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"60 Degrees Pharmaceuticals Signs Clinical Trial Agreements for Tafenoquine Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharma Receives FDA ODD for Tafenoquine for Acute Babesiosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Tafenoquine Clinical Trial for Babesiosis at Tufts","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"GSK","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK and MMV Launch New Medicine to Prevent Plasmodium vivax Malaria Relapse","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"July 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharma Announces IRB Approval for Tafenoquine Study in Babesiosis Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for Tafenoquine Succinate
Through the agreement, 60 Degrees will focus on advancing the development of Arakoda (tafenoquine succinate), which is being evaluated in the mid-stage clinical trial studies for treating Babesiosis.
Kozenis (tafenoquine) is the first single-dose, oral, hematin polymerization inhibitor co-administered with chloroquine for preventing P. vivax malaria relapse, launched in Thailand and Brazil.
Arakoda (tafenoquine succinate) is the inhibitor of hematin polymerization which is being evaluated in phase 2 clinical trials for the treatment of babesiosis patients.
Arakoda (tafenoquine succinate) is the inhibitor of hematin polymerization which is being evaluated in phase 2 clinical trials for the treatment of babesiosis patients.
Arakoda (tafenoquine succinate) is a USFDA approved small molecule drug which acts as a viral replication inhibitor. It is being evaluated for the treatment of candida auris infection.
The Company intends to use the net proceeds for the relaunch of the Company’s FDA-approved Arakoda (tafenoquine) an antimalarial indicated for the prophylaxis of malaria in. patients aged 18 years and older.
ARAKODA (tafenoquine) has not been proven safe to treat or prevent COVID-19. Testing for G6PD (Glucose6-phosphate dehydrogenase deficiency) is mandatory before prescribing ARAKODA.
Data from the TEACH study of tafenoquine, an 8-aminoquinoline, for the prevention of relapse of Plasmodium vivax (P. vivax) malaria in children and adolescents showed 95% of the study’s 60 subjects had no recurrence of P. vivax malaria during four months of follow-up.